Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor. Despite standard
multimodality treatment, the highly aggressive nature of GBM makes it one of the deadliest human malignancies.
The anti-cancer effects of dietary phytochemicals like curcumin provide new insights to cancer treatment.
Evaluation of curcumin’s efficacy against different malignancies including glioblastoma has been a motivational
research topic and widely studied during the recent decade. In this review, we discuss the recent observations
on the potential therapeutic effects of curcumin against glioblastoma. Curcumin can target multiple signaling
pathways involved in developing aggressive and drug-resistant features of glioblastoma, including pathways
associated with glioma stem cell activity. Notably, combination therapy with curcumin and chemotherapeutics
like temozolomide, the GBM standard therapy, as well as radiotherapy has shown synergistic response,
highlighting curcumin’s chemo- and radio-sensitizing effect. There are also multiple reports for curcumin nanoformulations
and targeted forms showing enhanced therapeutic efficacy and passage through blood-brain barrier,
as compared with natural curcumin. Furthermore, in vivo studies have revealed significant anti-tumor effects,
decreased tumor size and increased survival with no notable evidence of systemic toxicity in treated animals.
Finally, a pharmacokinetic study in patients with GBM has shown a detectable intratumoral concentration,
thereby suggesting a potential for curcumin to exert its therapeutic effects in the brain. Despite all the evidence in
support of curcumin’s potential therapeutic efficacy in GBM, clinical reports are still scarce. More studies are
needed to determine the effects of combination therapies with curcumin and importantly to investigate the potential
for alleviating chemotherapy- and radiotherapy-induced adverse effects.
Ex vivo expansion strategies of human hematopoietic stem cell (HSC) grafts with suboptimal stem cell dose have emerged as promising strategies for improving outcomes of HSC transplantation in patients with hematological malignancies. While exposure of HSCs to ex vivo cultures expands the number of phenotypically identifiable HSCs, it frequently alters the transcriptomic and metabolic profiles, therefore, compromising their long-term (LT) hematopoietic reconstitution capacity. Within the heterogeneous pool of expanded HSCs, the precise phenotypic, transcriptomic and metabolic profile and thus, the identity of HSCs that confer LT repopulation potential remains poorly described. Utilizing valproic acid (VPA) in ex vivo cultures of umbilical cord blood (UCB)-CD34+ cells, we demonstrate that expanded HSCs phenotypically marked by expression of the stem cell markers CD34, CD90 and EPCR (CD201) are highly enriched for LT-HSCs. Furthermore, we report that low mitochondrial membrane potential, and, hence, mitochondrial activity distinguishes LT-HSCs within the expanded pool of phenotypically defined HSCs. Remarkably, such reduced mitochondrial activity is restricted to cells with the highest expression levels of CD34, CD90 and EPCR phenotypic markers. Together, our findings reveal that high expression of CD34, CD90 and EPCR in conjunction with low mitochondrial activity is critical for identification of functional LT-HSCs generated within ex vivo expansion cultures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.